You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,692,767


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,692,767
Title: Solid solution beadlet
Abstract:Disclosed is a beadlet comprising (i) a hydrophobic long chain fatty acid or ester material; (ii) a surfactant; and (iii) a therapeutic agent which in admixture form a solid solution at room temperature. The hydrophobic material preferably has a melting point of about 40 to about 100.degree. C., and is most preferably glyceryl behenate. The surfactant is preferably a polyglycolyzed glyceride, polyoxyethylene sorbate, ethylene or propylene block copolymer or combinations thereof, and is most preferably polyoxyethylene 20 sorbitan monolaurate.
Inventor(s): Burnside; Beth A. (Silver Spring, MD), McGuinness; Charlotte M. (Bethesda, MD), Rudnic; Edward M. (North Potomac, MD), Couch; Richard A. (Bethesda, MD), Guo; Xiaodi (Derwood, MD), Tustian; Alexander K. (Bothell, WA)
Assignee: Shire Laboratories Inc. (Rockville, MD)
Application Number:09/156,464
Patent Claims:1. A composition comprising: at least one therapeutic agent and a solid beadlet having a size of from 50 microns to 1,000 microns, said beadlet comprising at least 20% by weight of at least one hydrophobic long chain fatty acid or glycerol ester thereof having 12 to 22 carbon atoms and at least 3.0% by weight of at least one surfactant, said at least one surfactant being a liquid at room temperature, said at least one surfactant being selected from the group consisting of ethylene or propylene oxide block copolymers, polyglycolyzed glycerides, sorbitan esters of stearate, sorbitan esters of laurate, polyethylene-polypropylene glycol block copolymers, sucrose long chain carboxylic acid esters, sucrose monoglycerides, sucrose diglycerides, sorbitan monoglycerides, sorbitan diglycerides. PEG derivatives of caprylic/capric acid triglycerides, and mixtures thereof, and said therapeutic agent being dispersed in said beadlet.

2. The composition of claim 1 wherein: the surfactant is present in an amount from about 3.0% to about 40% by weight; and; said at least one therapeutic agent is present in an amount from about 0.1% to about 70% by weight.

3. The composition of claim 1, wherein the hydrophobic long chain fatty acid or glycerol ester thereof has a melting point of from about 40 to about 100.degree. C.

4. The composition of claim 1, wherein the hydrophobic long chain fatty acid or glycerol ester thereof is glyceryl behenate.

5. The composition of claim 1 wherein said beadlet as a particle size hat does not exceed 500 microns.

6. The composition of claim 2 wherein said beadlet has a particle size from 100 microns to 350 microns.

7. The composition of claim 1 which further comprises sodium C.sub.9 -C.sub.30 alkyl sulfate or citric acid.

8. The composition of claim 1 which includes a fumed colloidal silicon dioxide glidant.

9. The composition of claim 1 wherein the therapeutic agent is acyclovir.

10. The composition of claim 1 wherein the therapeutic agent is dihydroergotamine.

11. The composition of claim 1 wherein the therapeutic agent is methylphenidate.

12. The composition of claim 1 which is coated with an immediate release, sustained-release or enteric-release coating.

13. The composition of claim 1 wherein the therapeutic agent is peptide, protein, or an analog thereof.

14. The composition of claim 1 wherein the therapeutic agent is selected from the group consisting of LHRH, TRH, vasopressin, leuprolide, desmopressin, calcitonin, parathyroid hormone, erythropoietin, enkephalin, growth hormone and interferon.

15. The composition of claim 1 wherein the therapeutic agent is an immunoactive agent elected from the group consisting of peptides, proteins, glycopolysaccharides and glycoproteins, as well as fragments and analogs with similar immunoactivity and at least 90% structural homology to the analog or fragment.

16. A pharmaceutical composition which comprises a plurality of the solid beadlet of claim 1 in a pharmaceutically acceptable carrier.

17. The composition of claim 16 wherein the beadlets contain a therapeutic agent selected from the group consisting of LHRH, leuprolide, desmopressin, calcitonin, parathyroid hormone and erythropoietin.

18. The composition of claim 16 which includes a fumed colloidal silicon dioxide glidant.

19. The composition of claim 16 which is in the form of a tablet.

20. The composition of claim 16 which is in the form of a buccal tablet.

21. The composition of claim 16 which is in the form of encapsulated single phase solid solution beadlets.

22. The composition of claim 1 wherein the surfactant is selected from t group consisting of polyglycolized glycerides, sorbitan esters of laurate, ethylene or propylene block copolymers or combinations thereof.

23. The composition of claim 22 wherein the surfactant is polyoxyethylene 20 sorbitan monolaurate.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.